Astrogenca tells the Supreme Court to listen to the negotiations of the drug challenging Medicare drug in the case
The Astrogenka Court has asked the Supreme Court to listen to his case by challenging the Medicare Drug Price discussion program made by the inflation reduction law (IRA).
According to the Supreme Court’s docket, the Astrogencar petition was filed on September 7. The company has asked the court to consider “IRA is involved in the interest of pharmaceutical manufacturers, which is protected by the appropriate process clause.”
In the first election of drugs for Medicare discussion, the drug was selected for astrogencar diabetes. Among the drugs in the following round, the calculation of its mantle cell lymphoma treatment was also chosen.
In his application, Astrazenka mentions the deadline facing it. The prices that agreed in the first phase of the bargain for Farxiga on January 5, 2021 were effective. Last year, the Biden administration revealed that they discussed the percent 5 percent discount on the Faroxiga list, the company agreed to sell it for $ 5.5, its list was $ 556.
“The case has expressed concern over the fate of a new government program that will overhaul the $ 600-billion prescription drug market and will affect the lives and health of Million0 million Americans admitted in Medicare,” Astrazenka wrote on her petition.
“Unlike its statutory name, it does not involve any real ‘discussion’. Rather, it forces pharmaceutical manufacturers to sell their most innovative and widely used drugs on unilaterally selected prices by Medicare and Mediced Services (CMS) centers on behalf of the Department of Health and Human Services (HHS).
Numerous other cases filed by drug makers and trade groups have been shot in the Federal Court, the judges have consistently discovered that the law is not unconstitutional.
In May, the Appellate Circuit Court dismissed the case of Astrogenca and confirmed the verdict of a lower court. The panel of the judges has properly rejected the claim of the drug maker’s unconstitutional or will suffer the IRA.
“The government has no interest in selling products (sponsored by sponsor or pharmaceutical benefits) at a higher price than when the government is willing to pay when paying these expenditures.”
“Pharma is recycling the same failed legal argument against Medicare’s discussion to maintain completely monopoly power,” said Marith Bessi, executive director of affordable drugs.
“From January 1, millions of patients in Medicare will start to see the low prices in life -saving actions with the Blockbuster Blockbuster Drug Farxiga,” he added. “After the defeat of the 5 courtrooms till today, this latest application is another attempt in the industry that is another attempt to limit the power of government to protect better contracts and to limit the power of government for the inevitable delay.”
